[go: up one dir, main page]

WO2012050370A3 - Composition pour prévenir ou traiter la polyarthrite rhumatoïde contenant un inhibiteur de sécrétase gamma en tant que composant actif - Google Patents

Composition pour prévenir ou traiter la polyarthrite rhumatoïde contenant un inhibiteur de sécrétase gamma en tant que composant actif Download PDF

Info

Publication number
WO2012050370A3
WO2012050370A3 PCT/KR2011/007611 KR2011007611W WO2012050370A3 WO 2012050370 A3 WO2012050370 A3 WO 2012050370A3 KR 2011007611 W KR2011007611 W KR 2011007611W WO 2012050370 A3 WO2012050370 A3 WO 2012050370A3
Authority
WO
WIPO (PCT)
Prior art keywords
secretase inhibitor
gamma secretase
reduces
rheumatoid arthritis
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/007611
Other languages
English (en)
Korean (ko)
Other versions
WO2012050370A2 (fr
Inventor
조동규
박종성
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sungkyunkwan University
Original Assignee
Sungkyunkwan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020110100981A external-priority patent/KR101330184B1/ko
Application filed by Sungkyunkwan University filed Critical Sungkyunkwan University
Publication of WO2012050370A2 publication Critical patent/WO2012050370A2/fr
Publication of WO2012050370A3 publication Critical patent/WO2012050370A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pour prévenir ou traiter la polyarthrite rhumatoïde contenant un inhibiteur de sécrétase gamma en tant que composant actif. L'inhibiteur de sécrétase gamma selon la présente invention réduit le degré d'induction d'arthrite et réduit l'afflux de cellules inflammatoires dans l'articulation du genou, de façon dose-dépendante, et réduit également la quantité de cytokines et de chimiokines, et réduit la quantité d'expression de NICD (domaine Notch intracellulaire). Par conséquent, l'inhibiteur de sécrétase gamma selon la présente invention peut être utilisé en tant que produit médicinal et aliment de santé fonctionnel qui est utile dans la prévention ou le traitement de la polyarthrite rhumatoïde, étant donné qu'il régule l'activation, la différenciation et la croissance de cellules immunitaires et a donc un effet remarquable dans la suppression de la production de NICD qui joue un rôle très important dans la transmission de signal Notch de telle manière que des réactions inflammatoires surviennent.
PCT/KR2011/007611 2010-10-15 2011-10-13 Composition pour prévenir ou traiter la polyarthrite rhumatoïde contenant un inhibiteur de sécrétase gamma en tant que composant actif Ceased WO2012050370A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20100100716 2010-10-15
KR10-2010-0100716 2010-10-15
KR1020110100981A KR101330184B1 (ko) 2010-10-15 2011-10-05 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물
KR10-2011-0100981 2011-10-05

Publications (2)

Publication Number Publication Date
WO2012050370A2 WO2012050370A2 (fr) 2012-04-19
WO2012050370A3 true WO2012050370A3 (fr) 2012-12-06

Family

ID=45938806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/007611 Ceased WO2012050370A2 (fr) 2010-10-15 2011-10-13 Composition pour prévenir ou traiter la polyarthrite rhumatoïde contenant un inhibiteur de sécrétase gamma en tant que composant actif

Country Status (1)

Country Link
WO (1) WO2012050370A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115364282A (zh) * 2022-09-05 2022-11-22 东莞市人民医院 双功能血管支架及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054633A1 (en) * 2003-09-09 2005-03-10 Alexander Flohr Malonamide derivatives
WO2009087130A1 (fr) * 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Utilisation d'un inhibiteur de la gamma-sécrétase pour le traitement du cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054633A1 (en) * 2003-09-09 2005-03-10 Alexander Flohr Malonamide derivatives
WO2009087130A1 (fr) * 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Utilisation d'un inhibiteur de la gamma-sécrétase pour le traitement du cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LUISTRO, LEOPOLDO ET AL.: "Preclinical Profile of a Potent gamma-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties", CANCER RESEARCH, vol. 69, no. 19, 22 September 2009 (2009-09-22), pages 7672 - 7680 *

Also Published As

Publication number Publication date
WO2012050370A2 (fr) 2012-04-19

Similar Documents

Publication Publication Date Title
EP4230623A3 (fr) Composés de pyridine en tant qu'inhibiteurs allostériques de shp2
WO2012112777A3 (fr) Biosynthèse d'oligosaccharides de lait humain dans des bactéries manipulées
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
MX346458B (es) Composicion probiotica para la salud bucal.
WO2010129285A3 (fr) Compositions antimicrobiennes et procédés d'utilisation apparentés
PH12019500714A1 (en) Antiseptic-tolerant lactic acid bacteria
MX2012000827A (es) Particulas que incorporan agentes antimicrobianos.
EA033436B1 (ru) Производные 5-фенокси-3н-пиримидин-4-она и их применение в качестве ингибиторов обратной транскриптазы вич
WO2012046030A3 (fr) Inhibiteurs de phosphodiestérase
UA109876C2 (uk) Композиція, що містить bifidobacterium longum cncm i-2618, для лікування та профілактики імунних розладів
GEP20207158B (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
MX2012013703A (es) Derivados de acido c-3-betulinico modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
PH12013500931A1 (en) Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
EP1941892A3 (fr) Agent antiallergénigue contenant une bactérie d' acide lactique
MY159379A (en) Composition for human and/or animal nutrition, uses thereof and yeasts
SG184347A1 (en) Non-nucleoside reverse transcriptase inhibitors
MX365046B (es) Formulacion de tableta oral que consiste de una combinacion fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares.
WO2011159129A3 (fr) Nouveaux dérivés de rhodanine, procédé pour les préparer et composition pharmaceutique pour la prévention ou le traitement du sida contenant les dérivés de rhodanine comme principes actifs
PH12013500735A1 (en) Powdered cereal compositions comprising non-replicating probiotic microorganisms
PH12013500811A1 (en) Extruded non-replicating probiotic micro-organisms and their health benefits
WO2008057300A3 (fr) Antagonistes de trpvi et leurs utilisations
EP4272832A3 (fr) Composés antimicrobiens, compositions et leurs utilisations
GB201200858D0 (en) Prebiotic powder composition and uses thereof
WO2011149301A3 (fr) Composition comprenant l'extrait de physalis alkekengi var. francheti hort en tant que principe actif pour la prévention et le traitement de maladies inflammatoires
PH12013500761A1 (en) Cysteine and food intake

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11832757

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11832757

Country of ref document: EP

Kind code of ref document: A2